Eculizumab in anti-factor H antibodies associated with atypical hemolytic uremic syndrome

Pediatrics

Volumn 133, Issue 6, 2014, Pages

  Diamante Chiodini, Benedetta ^a   Davin, Jean Claude ^a,b   Corazza, Francis ^c   Khaldi, Karim ^a   Dahan, Karin ^d   Ismaili, Khalid ^a   Adams, Brigitte ^a  

^a HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Anti Factor H autoantibodies; Atypical hemolytic uremic syndrome; Cardiomyopathy; Eculizumab; Multisystemic aHUS; Neurologic involvement; Thrombotic microangiopathy

Indexed keywords

COMPLEMENT FACTOR H; COMPLEMENT FACTOR H ANTIBODY; CREATININE; ECULIZUMAB; LACTATE DEHYDROGENASE; PROTEIN ANTIBODY; TROPONIN T; UNCLASSIFIED DRUG; UREA;

ABDOMINAL PAIN; AGITATION; ANEMIA; ARTICLE; ASTHENIA; BLOODY DIARRHEA; BRAIN DAMAGE; CASE REPORT; CHILD; COGNITIVE DEFECT; CONFUSION; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DELIRIUM; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG RESPONSE; ECHOGRAPHY; ELECTROCARDIOGRAM; FOLLOW UP; HEART DILATATION; HEART EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HEMATURIA; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; HYPOCOMPLEMENTEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGURIA; PERICARDIAL EFFUSION; PLASMA TRANSFUSION; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REFLEX DISORDER; RESPIRATORY DISTRESS; SCHOOL CHILD; THROMBOCYTOPENIA; UREA BLOOD LEVEL; VOMITING; WEIGHT REDUCTION;

ANTI-FACTOR H AUTOANTIBODIES; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CARDIOMYOPATHY; ECULIZUMAB; MULTISYSTEMIC AHUS; NEUROLOGIC INVOLVEMENT; THROMBOTIC MICROANGIOPATHY;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; BRAIN; BRAIN ISCHEMIA; CHILD; COMPLEMENT FACTOR H; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY MEDICAL INTERVENTION; ELECTROCARDIOGRAPHY; FOLLOW-UP STUDIES; HEMOGLOBINOMETRY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY FAILURE, CHRONIC; LACTIC ACID; LONG-TERM CARE; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIAL ISCHEMIA; RECURRENCE; RENAL DIALYSIS;

EID: 84901823978     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-1594     Document Type: Article

References (18)

1. Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologist needs to know in 2006? Nephrol Dial Transplant. 2005;20(12):2613-2619 (Pubitemid 41672257)
2. Caprioli J, Noris M, Brioschi S, et al International Registry of Recurrent and Familial HUS/TTP. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108(4):1267-1279 (Pubitemid 44232024)
3. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, et al French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18(8):2392-2400 (Pubitemid 47203855)
4. Dragon-Durey MA, Sethi SK, Bagga A, et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol. 2010;21(12):2180-2187
5. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med. 2008;59:293-309 (Pubitemid 351287939)
6. Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8 (11):643-657
7. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol. 2012;8(11):622-633
8. Rees L. Atypical HUS: time to take stock of current guidelines and outcome measures? Pediatr Nephrol. 2013;28(5):675-677
9. Noone D, Waters A, Pluthero FG, et al. Successful treatment of DEAP-HUS with eculizumab [published online ahead of print November 20, 2013]. Pediatr Nephrol.
10. Abu-Arafeh I, Gray E, Youngson G, Auchterlonie I, Russell G. Myocarditis and haemolytic uraemic syndrome. Arch Dis Child. 1995;72(1):46-47
11. Giordano M, Castellano G, Messina G, et al. Preservation of renal function in atypical hemolytic uremic syndrome by eculizumab: a case report. Pediatrics. 2012;130(5). Available at: www.pediatrics.org/cgi/content/full/130/ 5/e1385
12. Ariceta G, Besbas N, Johnson S, et al European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-696
13. Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):544-546
14. Lapeyraque AL, Frémeaux-Bacchi V, Robitaille P. Efficacy of eculizumab in a patient with factor-H-associated atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(4):621-624
15. Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol. 2009;4(8):1312-1316
16. Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost. 2010;36(6):633-640
17. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2014;10(3):174-180
18. Sallée M, Daniel L, Piercecchi MD, et al. Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant. 2010;25(6):2028-2032